<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:164da891-9f56-47c3-b0d9-bdba59636642,g:6f880fab-0048-4d9c-8565-722a42a40ed6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abus-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5581157-3db2-43ba-a912-7d65728d3fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cf6f6a29-ea74-486d-80a9-6b982178102b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5581157-3db2-43ba-a912-7d65728d3fb1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cf6f6a29-ea74-486d-80a9-6b982178102b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_100b825b-e934-46ed-a6e1-6ccf9d532e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5581157-3db2-43ba-a912-7d65728d3fb1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_100b825b-e934-46ed-a6e1-6ccf9d532e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_78e3e064-b16c-4a00-ba16-67184af9ef96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5581157-3db2-43ba-a912-7d65728d3fb1" xlink:to="loc_us-gaap_LiabilitiesCurrent_78e3e064-b16c-4a00-ba16-67184af9ef96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_60bd77e7-128a-4d06-9b54-41142dcc4787" xlink:href="abus-20211231.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5581157-3db2-43ba-a912-7d65728d3fb1" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_60bd77e7-128a-4d06-9b54-41142dcc4787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef600c44-7f33-4bdc-aa62-9a5beef4ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0316712e-361b-456c-850f-ec390769285c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ef600c44-7f33-4bdc-aa62-9a5beef4ec18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0316712e-361b-456c-850f-ec390769285c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5a298d0d-c3bc-4959-8bec-cd1a5de2342f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ef600c44-7f33-4bdc-aa62-9a5beef4ec18" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5a298d0d-c3bc-4959-8bec-cd1a5de2342f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7f56c0be-02c0-444d-bb3d-9fdb430119c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_a06716a8-1e91-4dce-bcc3-226e8cb7d070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f56c0be-02c0-444d-bb3d-9fdb430119c9" xlink:to="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_a06716a8-1e91-4dce-bcc3-226e8cb7d070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6bb3e7c2-cf0e-4e76-96f9-3c0ced081d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f56c0be-02c0-444d-bb3d-9fdb430119c9" xlink:to="loc_us-gaap_CommonStockValue_6bb3e7c2-cf0e-4e76-96f9-3c0ced081d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4f97b4ac-632e-4bd0-82c3-81561e29c7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f56c0be-02c0-444d-bb3d-9fdb430119c9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4f97b4ac-632e-4bd0-82c3-81561e29c7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8fb931ef-6f02-4724-8a41-cec94177a859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f56c0be-02c0-444d-bb3d-9fdb430119c9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8fb931ef-6f02-4724-8a41-cec94177a859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cea770e4-80cd-463e-a642-0e1cbfa4ae03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f56c0be-02c0-444d-bb3d-9fdb430119c9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cea770e4-80cd-463e-a642-0e1cbfa4ae03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f5b17f41-2dda-4fa0-a5a5-fb7e727ec941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_877e1d5a-f905-4c24-bec2-a860b4e4542c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f5b17f41-2dda-4fa0-a5a5-fb7e727ec941" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_877e1d5a-f905-4c24-bec2-a860b4e4542c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b8e11366-9156-42d4-9226-e75369c1c4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f5b17f41-2dda-4fa0-a5a5-fb7e727ec941" xlink:to="loc_us-gaap_ShortTermInvestments_b8e11366-9156-42d4-9226-e75369c1c4c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_043ad35c-aaff-478d-bc3a-1e2c2f0f6ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f5b17f41-2dda-4fa0-a5a5-fb7e727ec941" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_043ad35c-aaff-478d-bc3a-1e2c2f0f6ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e2017cce-ef20-4b7e-92be-471e7db91a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f5b17f41-2dda-4fa0-a5a5-fb7e727ec941" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e2017cce-ef20-4b7e-92be-471e7db91a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d209adb1-bbfd-4a29-af08-c83b4144ecf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_918ddcd8-47a9-42e3-aef0-fcc0c5258386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d209adb1-bbfd-4a29-af08-c83b4144ecf5" xlink:to="loc_us-gaap_Liabilities_918ddcd8-47a9-42e3-aef0-fcc0c5258386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df4e0f52-8f32-440b-a11f-fcf22c7d6151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d209adb1-bbfd-4a29-af08-c83b4144ecf5" xlink:to="loc_us-gaap_StockholdersEquity_df4e0f52-8f32-440b-a11f-fcf22c7d6151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f23f323c-8631-4ca2-8de8-c699766bc0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1ce9212e-8c3e-49b6-8482-e4138d941565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f23f323c-8631-4ca2-8de8-c699766bc0a8" xlink:to="loc_us-gaap_AssetsCurrent_1ce9212e-8c3e-49b6-8482-e4138d941565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_574156f2-8952-4133-826b-bc8e189fe0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f23f323c-8631-4ca2-8de8-c699766bc0a8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_574156f2-8952-4133-826b-bc8e189fe0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_8923605b-95ab-47d4-af4b-b1cb530d6f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f23f323c-8631-4ca2-8de8-c699766bc0a8" xlink:to="loc_us-gaap_LongTermInvestments_8923605b-95ab-47d4-af4b-b1cb530d6f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_51850824-6f4c-459b-8941-0a63e1473355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f23f323c-8631-4ca2-8de8-c699766bc0a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_51850824-6f4c-459b-8941-0a63e1473355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b6a2876-21d9-4fc7-9bcc-9f83c8c65391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f23f323c-8631-4ca2-8de8-c699766bc0a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b6a2876-21d9-4fc7-9bcc-9f83c8c65391" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="abus-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_341d219f-8d20-405f-8bb6-d1c331215c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_815cec4e-2148-4556-9704-945361f5ec14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_341d219f-8d20-405f-8bb6-d1c331215c89" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_815cec4e-2148-4556-9704-945361f5ec14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_90982ee6-5152-4411-846b-434c50492292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_341d219f-8d20-405f-8bb6-d1c331215c89" xlink:to="loc_us-gaap_NetIncomeLoss_90982ee6-5152-4411-846b-434c50492292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0218b858-c22c-4914-96c4-2430257d4869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_51f581d0-c462-4466-90c9-fdea1a6931fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0218b858-c22c-4914-96c4-2430257d4869" xlink:to="loc_us-gaap_OperatingIncomeLoss_51f581d0-c462-4466-90c9-fdea1a6931fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ba046c22-1c8f-4d13-80ef-793b1d48d16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0218b858-c22c-4914-96c4-2430257d4869" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ba046c22-1c8f-4d13-80ef-793b1d48d16b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_51dc848c-9b58-4d48-a8d2-fbe07df852ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6b031df3-2c46-4270-bd48-e032c74f00d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_51dc848c-9b58-4d48-a8d2-fbe07df852ed" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6b031df3-2c46-4270-bd48-e032c74f00d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d62f3a44-5b82-40c2-a77d-a83be0d68c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_51dc848c-9b58-4d48-a8d2-fbe07df852ed" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d62f3a44-5b82-40c2-a77d-a83be0d68c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3dbd0bd7-4a63-4010-82d5-4b74e80eec2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_51dc848c-9b58-4d48-a8d2-fbe07df852ed" xlink:to="loc_us-gaap_InterestExpense_3dbd0bd7-4a63-4010-82d5-4b74e80eec2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e973e44b-c7f2-4c51-8124-1a389101c04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_51dc848c-9b58-4d48-a8d2-fbe07df852ed" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e973e44b-c7f2-4c51-8124-1a389101c04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a6cdfa14-2890-476b-8aa2-bff4a5d8fde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9f5be37d-d30a-4d36-b490-c0560415e709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a6cdfa14-2890-476b-8aa2-bff4a5d8fde5" xlink:to="loc_us-gaap_RestructuringCharges_9f5be37d-d30a-4d36-b490-c0560415e709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a82971d6-1785-471b-98e2-64ef75904a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a6cdfa14-2890-476b-8aa2-bff4a5d8fde5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a82971d6-1785-471b-98e2-64ef75904a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d5163b0a-b574-448b-8196-48b0725a62b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a6cdfa14-2890-476b-8aa2-bff4a5d8fde5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d5163b0a-b574-448b-8196-48b0725a62b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0c8ef189-846e-407a-b277-50338ed80ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a6cdfa14-2890-476b-8aa2-bff4a5d8fde5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0c8ef189-846e-407a-b277-50338ed80ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4583c979-2206-404a-b5f4-84a31d4849fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_36284be8-1139-4c3e-981d-1fa042c1df38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4583c979-2206-404a-b5f4-84a31d4849fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_36284be8-1139-4c3e-981d-1fa042c1df38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e316011-5cd6-4da7-be1f-34b419f625ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4583c979-2206-404a-b5f4-84a31d4849fd" xlink:to="loc_us-gaap_NetIncomeLoss_4e316011-5cd6-4da7-be1f-34b419f625ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_52626d5c-9e23-4e64-a59f-2ae84ed8b45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4583c979-2206-404a-b5f4-84a31d4849fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_52626d5c-9e23-4e64-a59f-2ae84ed8b45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef44a598-c45a-4c7e-82be-8ee548fab293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b94a0210-5d9d-4896-851d-b497218e85eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef44a598-c45a-4c7e-82be-8ee548fab293" xlink:to="loc_us-gaap_OperatingExpenses_b94a0210-5d9d-4896-851d-b497218e85eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ec2f31cf-f6d1-4b96-9313-571440e3500a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef44a598-c45a-4c7e-82be-8ee548fab293" xlink:to="loc_us-gaap_Revenues_ec2f31cf-f6d1-4b96-9313-571440e3500a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="abus-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5471c809-feb0-4e87-9b32-fa618ad541ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2519cc9-94af-4809-836f-027ce8ec5331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5471c809-feb0-4e87-9b32-fa618ad541ef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2519cc9-94af-4809-836f-027ce8ec5331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_57bda5bf-fc7a-4bd3-b9c8-2a2c9b459c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5471c809-feb0-4e87-9b32-fa618ad541ef" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_57bda5bf-fc7a-4bd3-b9c8-2a2c9b459c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f82f40c8-7c0b-4ec5-aa8d-7a8e9e66a7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5471c809-feb0-4e87-9b32-fa618ad541ef" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f82f40c8-7c0b-4ec5-aa8d-7a8e9e66a7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adda873-6506-45d6-a2ee-03df2cecc53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9869f1f8-ee8a-4d57-a8a9-2cf7d5a9b0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adda873-6506-45d6-a2ee-03df2cecc53b" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9869f1f8-ee8a-4d57-a8a9-2cf7d5a9b0ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a7e11e21-7df0-48ba-9161-13c4eef5583d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adda873-6506-45d6-a2ee-03df2cecc53b" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a7e11e21-7df0-48ba-9161-13c4eef5583d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8f41f63e-f077-4f81-bce9-2c37bf598aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adda873-6506-45d6-a2ee-03df2cecc53b" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8f41f63e-f077-4f81-bce9-2c37bf598aca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b3a90cf-8b1b-4e5f-ab34-f1a9185591a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7adda873-6506-45d6-a2ee-03df2cecc53b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b3a90cf-8b1b-4e5f-ab34-f1a9185591a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52f6bf53-673c-408f-8c08-b2755de6e906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_NetIncomeLoss_52f6bf53-673c-408f-8c08-b2755de6e906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0cad4a5f-052d-48d6-b5c2-e820390e2835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0cad4a5f-052d-48d6-b5c2-e820390e2835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a371d82f-1e21-46ba-a9ea-c727e2585d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a371d82f-1e21-46ba-a9ea-c727e2585d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dc669b7b-2be1-456f-8f97-118dd2a5ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dc669b7b-2be1-456f-8f97-118dd2a5ea05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_acc4cc60-97c1-46be-9eee-e049d3ae29ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_acc4cc60-97c1-46be-9eee-e049d3ae29ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_36dfa7e6-26f5-42df-b48f-617bae3efe1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_ShareBasedCompensation_36dfa7e6-26f5-42df-b48f-617bae3efe1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Netequityinvestmentgainorloss_f5645737-d946-4897-96ac-b9117433d8e0" xlink:href="abus-20211231.xsd#abus_Netequityinvestmentgainorloss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_abus_Netequityinvestmentgainorloss_f5645737-d946-4897-96ac-b9117433d8e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_42b022b6-f481-4bec-99b2-549bd9306583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_Depreciation_42b022b6-f481-4bec-99b2-549bd9306583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_90def0f7-6531-4585-82c6-eda2e8eccea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_90def0f7-6531-4585-82c6-eda2e8eccea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_52902adb-dfe8-46c3-ae10-ceba7f235e68" xlink:href="abus-20211231.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_52902adb-dfe8-46c3-ae10-ceba7f235e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_db46c503-4056-4f89-9624-f2a470a18b24" xlink:href="abus-20211231.xsd#abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_db46c503-4056-4f89-9624-f2a470a18b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a6f1587a-5ed5-4073-b090-bb02000e572e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a6f1587a-5ed5-4073-b090-bb02000e572e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9224df3c-e754-4f84-b64c-9a8e3f2d4188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19913dd3-ce1e-4a11-bd46-3a503ef2bac2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9224df3c-e754-4f84-b64c-9a8e3f2d4188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13d4efa-bd3c-4518-a4ac-b6293673dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1fa071e-3ad8-43d3-9c5f-7a38dda79366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13d4efa-bd3c-4518-a4ac-b6293673dcf7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1fa071e-3ad8-43d3-9c5f-7a38dda79366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce967186-c82a-4c9e-b2d9-fccad401e398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13d4efa-bd3c-4518-a4ac-b6293673dcf7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce967186-c82a-4c9e-b2d9-fccad401e398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6262cc32-f167-468c-89cc-aa1b0c96191b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13d4efa-bd3c-4518-a4ac-b6293673dcf7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6262cc32-f167-468c-89cc-aa1b0c96191b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b52e3eaf-e40f-487b-a2e8-ae2db47f6ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e13d4efa-bd3c-4518-a4ac-b6293673dcf7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b52e3eaf-e40f-487b-a2e8-ae2db47f6ffc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6e3613df-f53e-4e44-b758-0d8d1e5f22a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4d8e2098-1d9d-4e42-a87c-5f065f3e3b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6e3613df-f53e-4e44-b758-0d8d1e5f22a6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4d8e2098-1d9d-4e42-a87c-5f065f3e3b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b4bac23-466d-404e-9ebf-79304987e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6e3613df-f53e-4e44-b758-0d8d1e5f22a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b4bac23-466d-404e-9ebf-79304987e1f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_27f597c3-1130-4286-b44c-ffa79223350b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c02e08c-d828-4f85-88fb-9b9ce115dfef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_27f597c3-1130-4286-b44c-ffa79223350b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c02e08c-d828-4f85-88fb-9b9ce115dfef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_70ba3740-c414-4e19-94d0-954a8429d491" xlink:href="abus-20211231.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_27f597c3-1130-4286-b44c-ffa79223350b" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_70ba3740-c414-4e19-94d0-954a8429d491" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#InvestmentsinmarketablesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54daf46f-3308-4a10-a630-855c7381922e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9eeb36ba-bd04-4bc4-99b3-72cbd2eaa3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54daf46f-3308-4a10-a630-855c7381922e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9eeb36ba-bd04-4bc4-99b3-72cbd2eaa3d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b1cca122-b7b5-4c8f-b7f8-56cab93728b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54daf46f-3308-4a10-a630-855c7381922e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b1cca122-b7b5-4c8f-b7f8-56cab93728b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d04b9e82-6b6a-4979-aadf-e7eb67226afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54daf46f-3308-4a10-a630-855c7381922e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d04b9e82-6b6a-4979-aadf-e7eb67226afc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#LeasesMaturityofleaseliabilityDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85cb3a22-f2b0-4fbc-8d9c-e275b7970e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b858965-d4c5-40c9-a7f2-645908cbff22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85cb3a22-f2b0-4fbc-8d9c-e275b7970e6a" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b858965-d4c5-40c9-a7f2-645908cbff22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_098251fc-4737-4284-ab91-c272d7e83e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85cb3a22-f2b0-4fbc-8d9c-e275b7970e6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_098251fc-4737-4284-ab91-c272d7e83e72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails_1" xlink:type="simple" xlink:href="abus-20211231.xsd#LeasesMaturityofleaseliabilityDetails_1"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_04e65e56-2675-40e4-9887-733fdd98cfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_04e65e56-2675-40e4-9887-733fdd98cfa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0770bd08-2d0d-4a0a-9dc9-13d7e3efc6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0770bd08-2d0d-4a0a-9dc9-13d7e3efc6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9c6c7d39-d8ad-4088-a5a6-81074488d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9c6c7d39-d8ad-4088-a5a6-81074488d7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d4b067f6-254f-4a03-954e-126ee4f3712f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d4b067f6-254f-4a03-954e-126ee4f3712f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_292aab72-1bec-4352-8d2a-821d7b6fff56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_292aab72-1bec-4352-8d2a-821d7b6fff56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2c023b27-ad40-435a-8ea9-a6ff1692cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f33e0c89-82af-4663-8d28-9933179fff46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2c023b27-ad40-435a-8ea9-a6ff1692cf55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#PropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_af4b865d-728c-4ee6-acab-4f71cd344828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_40137f2a-43e7-49ed-9438-ff62f63e2108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_af4b865d-728c-4ee6-acab-4f71cd344828" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_40137f2a-43e7-49ed-9438-ff62f63e2108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6a7397c9-d78b-4431-b4ea-84af3d8b7625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_af4b865d-728c-4ee6-acab-4f71cd344828" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6a7397c9-d78b-4431-b4ea-84af3d8b7625" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#AccountspayableandaccruedliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_88602662-bf3b-405e-8884-9cf0296a15e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_88602662-bf3b-405e-8884-9cf0296a15e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_04a806c8-f193-4908-84d7-aa3ec8b909ff" xlink:href="abus-20211231.xsd#abus_AccruedResearchandDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:to="loc_abus_AccruedResearchandDevelopmentCurrent_04a806c8-f193-4908-84d7-aa3ec8b909ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_2cf40aed-25d4-44fc-bfd5-3f9591e0b543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_2cf40aed-25d4-44fc-bfd5-3f9591e0b543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedPayrollCurrent_591908ed-1491-4900-9ac9-4c7ce4a86342" xlink:href="abus-20211231.xsd#abus_AccruedPayrollCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:to="loc_abus_AccruedPayrollCurrent_591908ed-1491-4900-9ac9-4c7ce4a86342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_124d6add-6c6a-4367-a516-5a0d4bf9b39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_124d6add-6c6a-4367-a516-5a0d4bf9b39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_948ecdbc-86d4-484a-9aa0-d40a292af21f" xlink:href="abus-20211231.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstanding"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5ac0dd82-5819-4ec4-bacc-4314b3a58004" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_948ecdbc-86d4-484a-9aa0-d40a292af21f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncometaxesIncometaxreconciliationDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#IncometaxesIncometaxreconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncometaxesIncometaxreconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d8620148-8740-4f65-a93c-2e475b442fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d8620148-8740-4f65-a93c-2e475b442fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_735bb3c7-2c36-440a-802c-0924b6be4cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_735bb3c7-2c36-440a-802c-0924b6be4cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsInvestment_6ceb33b1-b8a8-4639-bc9c-370aeeed1b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsInvestment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsInvestment_6ceb33b1-b8a8-4639-bc9c-370aeeed1b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_9f528d63-ee6f-4a61-9dec-870732acee40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_9f528d63-ee6f-4a61-9dec-870732acee40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_d1ead0fb-e071-404a-b7c9-7e691c2e730e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_d1ead0fb-e071-404a-b7c9-7e691c2e730e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_76b8ab0e-ccb1-4f8e-b876-ad921a24b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_76b8ab0e-ccb1-4f8e-b876-ad921a24b66c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_46a6f8a5-abb7-45a3-a155-24a128b520bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_46a6f8a5-abb7-45a3-a155-24a128b520bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_34cc8db2-e458-46db-8204-7dfcd0b7a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_34cc8db2-e458-46db-8204-7dfcd0b7a92f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_82d5a695-19bd-4cca-9c1a-32aa06e9ab80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_38037b84-d025-41f1-8dab-9be17c912256" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_82d5a695-19bd-4cca-9c1a-32aa06e9ab80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncometaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="abus-20211231.xsd#IncometaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncometaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8fb82f56-dc2a-4271-bb26-a2883e6cc6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetsLiabilitiesGross_61c17930-e003-481c-ab0d-a599f2a2588f" xlink:href="abus-20211231.xsd#abus_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8fb82f56-dc2a-4271-bb26-a2883e6cc6e3" xlink:to="loc_abus_DeferredTaxAssetsLiabilitiesGross_61c17930-e003-481c-ab0d-a599f2a2588f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2d452833-f80a-4601-8b90-aa8c616402d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8fb82f56-dc2a-4271-bb26-a2883e6cc6e3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2d452833-f80a-4601-8b90-aa8c616402d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:href="abus-20211231.xsd#abus_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions_7bb9f34f-add1-4946-b323-61c68ed32733" xlink:href="abus-20211231.xsd#abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions_7bb9f34f-add1-4946-b323-61c68ed32733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2b685575-e664-41a1-9178-08c944a0f351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2b685575-e664-41a1-9178-08c944a0f351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1d724825-11ee-4e84-9d87-35c5944787d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1d724825-11ee-4e84-9d87-35c5944787d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a81bbb21-90c1-4495-8a9d-8e83e56928e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a81bbb21-90c1-4495-8a9d-8e83e56928e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_5e1b1ddc-29d2-4307-9dac-2b20bfdf126b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_5e1b1ddc-29d2-4307-9dac-2b20bfdf126b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_b64cce00-136b-4fea-b6c7-b87feb99f60a" xlink:href="abus-20211231.xsd#abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_b64cce00-136b-4fea-b6c7-b87feb99f60a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1fdc21b6-2ff5-467b-8d59-15f564756bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1fdc21b6-2ff5-467b-8d59-15f564756bab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_ea1d7154-cb5a-4eb5-bdb7-9d20d14e10a5" xlink:href="abus-20211231.xsd#abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_ea1d7154-cb5a-4eb5-bdb7-9d20d14e10a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_8feaed55-39b3-4d02-871d-d136aa6c2b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_8feaed55-39b3-4d02-871d-d136aa6c2b9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_c24501b4-6a67-400b-b3e0-e23f3c07dba3" xlink:href="abus-20211231.xsd#abus_DeferredTaxAssetBookAmortizationInExcessOfTax"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_1c8b059a-519b-42f5-9324-fa6ce0b57364" xlink:to="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_c24501b4-6a67-400b-b3e0-e23f3c07dba3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
